Jun 29, 2026 – 10.49amMedical AI software company EchoIQ has launched a $100 million capital raising to take on the $US65 billion heart failure market and fund the commercialisation of its disease detection products.Echo IQ is using artificial intelligence and data to improve diagnosis of structural heart disease. Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
EchoIQ launches $100m raising for US heart market push
Street Talk first flagged the fundraising effort on Sunday after the $1 billion market cap company began wall crossing investors.
TL;DRAI
EchoIQ raises $100M to commercialize AI diagnostics for structural heart disease targeting the $65B US market. Signal: medtech AI moves to production with defensible moats (regulatory approval, reimbursement, accuracy), establishing sustainable GTM for infrastructure-heavy AI.
142 words~1 min read
